Future studies should expand the sample size, incorporate multicenter data for validation, and focus on the specific mechanism of action of CHI3L1 in aggressive lymphomas, especially its interactions with key signaling pathways and cellular processes. This evidence concerns the gene CHI3L1 and lymphoma.